Heidelberg Biotech Emerges with Novel Strategy to Target Heart Disease

Jan de Vries · 2026-08-28

A new player has just entered the European biotech scene with a fresh take on treating some of the world's most common and challenging diseases. Revier Therapeutics, based in Heidelberg, Germany, has officially launched with a $6.4 million Seed funding round. It's not just another startup, though. They're tackling cardiometabolic diseases—think heart failure and atherosclerosis—with a scientific approach that aims to be more precise than what's come before. This initial funding was spearheaded by the KHAN Technology Transfer Fund II. They were joined by High-Tech Gründerfonds (HTGF), VORNvc, and a group of private investors coordinated through Revier Invest Heidelberg. It's a solid coalition backing a big idea right from the start. ### The Unmet Need in Heart Health Let's be clear about the problem. We've made huge strides in cardiovascular medicine, but there are still massive gaps. Millions of patients living with specific conditions like HFpEF (heart failure with preserved ejection fraction) and ASCVD (atherosclerotic cardiovascular disease) simply don't have great, targeted treatment options. The existing tools often manage symptoms rather than getting at the root cause. Prof. Eva van Rooij, the company's co-founder and CEO, put it this way: “We believe the next generation of medicines needs to address the underlying disease-driving biology. That’s the only way to deliver solutions that are both impactful and lasting for patients.” Their whole mission is built on that premise. ### A Different Kind of HDAC Inhibitor So, what's their secret sauce? It's all about a specific class of enzymes called HDACs (histone deacetylases). These enzymes are involved in a bunch of severe diseases. Past attempts to target them were a bit like using a sledgehammer—they hit too many types of HDACs at once, leading to nasty side effects that limited how much medicine a patient could take. Revier is trying a more surgical strike. They've developed the first therapeutic approach designed to selectively target only class IIa HDACs. Their drugs are small molecules you can take orally, and they're engineered to block the bad, disease-causing activity of these enzymes while leaving their healthy functions alone. - **Precision Targeting:** Focuses only on class IIa HDACs, avoiding the broader, problematic inhibition of other classes. - **Oral Availability:** Designed as pills, not injections, aiming for better patient compliance. - **Disease-Modifying Goal:** The aim isn't just symptom relief, but to actually alter the course of the disease. Prof. Johannes Backs, the scientific founder, explains the advantage: “Our compounds specifically inhibit the disease-driving activity while preserving essential functions. This precision is designed to be effective *and* safe.” It's a classic case of wanting the benefits without the baggage. ### Why Investors Are Betting on This Science This isn't just academic excitement. The investors see a clear path from lab bench to patient bedside. Michael Hamacher from KHAN Technology Transfer Fund II highlighted the combination of a “differentiated strategy” and an “exceptional leadership team.” He believes Revier has a “unique opportunity to reshape the standard of care” by providing long-term benefits for patients. That $6.4 million in seed capital now has a clear job. The company plans to push its two lead programs forward: 1. Its primary program targeting HFpEF. 2. A second program focused on ASCVD. The money will also help them build out the full team—operations, science, and clinical functions—needed to move from preclinical research toward human trials. It's the critical first step in a long journey, but one they're now funded to begin. For professionals watching the European startup and biotech incorporation landscape, Revier Therapeutics is a name to remember. It embodies the deep-science, high-potential ventures that make the region's life sciences sector so compelling.